Introduction

Autism spectrum disorder (ASD) includes a group of developmental disorders that can result in social, behavioral, and communication problems. The Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) defines ASD as: Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history: Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions.

Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication. Deficits in developing, maintaining, and understanding relationships, ranging, for example, from difficulties adjusting behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; to absence of interest in peers [1].

The overall prevalence of ASD is estimated to be 1 of 68 children. The average ratio of ASD in males compared to females is 4.5:1. In ASD, common problems that arise are aggression, self-injurious behavior, and irritability [2]. These maladaptive behaviors can lead to patients with ASD to be placed in restrictive home or school settings, increase risk of victimization, and place severe burden on caretakers [3].

Intellectual disability (ID) is defined as deficits in intellectual functioning and adaptive behavior before the age of 18 in the DSM-V and by the American Association on Intellectual and Developmental Disabilities (AAIDD). Intellectual functioning or intelligence refers to mental tasks such as learning or reasoning, which can be assessed with an Intelligence Quotient (IQ) score that is usually 2 standard deviations below the mean in ID. Adaptive behavior refers to conceptual, social, and practical skills used in multiple settings, such as home or school situations. ID is more common in males than females and is seen more frequently in individuals of lower socioeconomic status (SES) than mid to high SES [4,5]. Aggressive behavior is cited as a common challenge in the individuals diagnosed with ID and behavioral disturbances are often treated with antipsychotics. However, there is no official treatment for aggression in patients diagnosed with ID and previous studies have shown that Risperidone and Haloperidol were not effective compared to placebo [6] (Table 1).
Atypical antipsychotics act via blockade of post-synaptic dopamine and serotonin receptors, or some may work by acting as a partial agonist. They are preferred over typical antipsychotics due to their side effect profile and have been found useful in the treatment of severe maladaptive behavior in children with ASD. Currently, Risperidone and Aripiprazole, two atypical antipsychotics, have been approved for the treatment of tantrums, aggression, or self-injurious behavior in children with ASD [3, 7-9]. There is also preliminary evidence for the potential use of Simvastatin as an adjunct to Risperidone in the treatment of irritability in ASD patients [10]. Despite the limited data on atypical antipsychotics use in ASD and pediatric patients, there have been developments in the field. Lurasidone, an atypical antipsychotic, has been shown to cause clinical improvement in adolescents diagnosed with schizophrenia, leading to its approval for treatment in this population. Furthermore, Asenapine has also been approved to treat childhood bipolar I disorder. Asenapine is another atypical antipsychotic that has shown clinical effectiveness based on the Young-Mania Rating Scale (YMRS) [11-14].

Oxytocin and arginine vasopressin have become attractive potential therapeutic targets for ASD research because they are key regulators of social behavior [15]. Recent studies show evidence of the use of oxytocin metabolites, such as OT (4-9), to improve sociability in ASD patients. This discovery shows the possibility of a new drug discovery pathway for ASD [16]. Another approach for improving socialization and communication includes the use of vasopressin V1a receptor antagonists, such as Balovaptan, which demonstrated improvement in Vineland-II socialization and communication scores in a phase two clinical trial [17].

Supplementation of Vitamin D and omega-3-fatty acids is correlated with improving the irritability symptoms of children with ASD. Vitamin D has also been shown to improve hyperactivity symptoms in children [18, 19]. Insufficient Vitamin D is common in autistic children and may also be associated as a risk factor for developing ASD [20]. Additionally, Vitamin B supplementation is associated with decreasing behavioral problems in ASD patients, although it is unclear as to exactly how it is effective. Vitamin B6 is critical in the synthesis of several neurotransmitters; including serotonin, dopamine, and others; as a result, it is surmised that Vitamin B supplementation can treat impaired neurotransmitter systems [21].

There is still further research to be conducted on the use of pharmacotherapy in patients with ASD and ID. Cariprazine has not been studied. This retrospective study aims to analyze the efficacy of the second-generation atypical antipsychotic drug Cariprazine for the treatment of aggressive behavior in those with autism spectrum disorder and intellectual disability.

### Cariprazine

Cariprazine is an atypical antipsychotic, FDA approved for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. The precise mechanism of Cariprazine is unknown in schizophrenia and bipolar disorder. It is thought to be effective due to its partial agonist activity at the dopamine D2 receptor and serotonin 5HT1A receptor and antagonism at the serotonin 5HT2A receptor. Additionally, Cariprazine has high affinity for Dopamine D3 receptors acting as a partial agonist at D3 receptors. Cariprazine is primarily metabolized by CYP3A4 into Desmethyl Cariprazine (DCAR) and DCAR is then further metabolized by CYP3A4 into Didesmethyl Cariprazine (DDCAR). DCAR and DDCAR both
display similar pharmacological potency as Cariprazine. The half-life of Cariprazine ranges from 2-4 days and its two active metabolites, DCAR and DDCAR, have half-lives ranging from 1-3 weeks, making it the atypical antipsychotic with the longest half-life. The peak plasma concentration of Cariprazine occurs in 3-6 hours. Cariprazine and DCAR reach steady state in 1-2 weeks, whereas DDCAR reaches steady state in 4-8 weeks.

Commonly observed adverse reactions (incidence ≥ 5% and at least twice that for placebo) were: Schizophrenia: extrapyramidal symptoms and akathisia. Bipolar Mania: extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence and restlessness.

The chemical name of Cariprazine is trans-N-[4-[2-[4-(2,3-dichlorophenyl) piperazine-1-yl] ethyl] cyclohexyl]-N', N'-dimethylurea hydrochloride. Its molecular formula is C21H33Cl3N4O and its molecular weight is 463.9 g/mol [22-24].

Figure 1: Its molecular formula is C21H33Cl3N4O and its molecular weight is 463.9 g/mol.

Material and Methods

We reviewed the charts of over 120 patients at the Developmental Disabilities Center of Mount Sinai West Hospital and identified eight patients receiving the target drug (Cariprazine). We then retrospectively reviewed each patient’s chart to assign a CGI-S score to each patient before each was prescribed Cariprazine and again at the time of investigation to determine a CGI-I and CGI-E score. Co-morbid conditions and concurrent medications during treatment with Cariprazine were noted.

Clinical Global Impression (CGI) scales are used as measures of symptom severity alongside treatment response as judged by a trained clinician. The severity scale (CGI-S) is a seven-point scale used to assign symptom severity at time of assessment, usually prior to initiating a treatment modality. The values are defined as 1, normal or not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, among the most extremely ill.

The improvement scale (CGI-I) is a seven-point scale used to assess a patient’s improvement, if any, from the baseline CGI-S due to drug treatment. Its values are defined as 1, very much improved; 2, much improved; 3, minimally improved; 4, no improvement; 5, minimally worse; 6, much worse; or 7, very much worse.

The efficacy index (CGI-E) consists of a 4-point x 4-point rating scale and assesses the therapeutic effect and side effect of the treatment. The therapeutic effect can be scored as marked (vast improvement), moderate (partial remission), minimal (slight improvement), or unchanged or worse. The side effect can be scored as none, no significant interference with functioning, significant interfering with functioning or side effect outweighs therapeutic effect. CGI-E score can range from 1-16. A score of 1 indicates vast improvement with no side effects and a score of 16 signifies unchanged or worsened functioning with side effects outweighing therapeutic effect [25].

Results and Discussion

The sample included 2 female and 6 male cases. Mean patient age of the sample was 38 years old (range 15 to 64 years old). Mean length of time on Cariprazine was 4.5 months (range 1 to 7 months). Mean titrated total daily dose was 1.88mg (range 1.5 to 3.0mg) (Figure 2). Cases were retrospectively chart reviewed for Clinical Global Impression Severity Scale (CGI-S) before initiating Cariprazine and Clinical Global Impression Improvement Scale (CGI-I) and Clinical Global Impression Efficacy Scale (CGI-E) after initiating Cariprazine. The mean CGI-S of the sample was 5.75 (range 5 to 7), which correlates with marked to severe illness, and mean CGI-I of the sample was 2.13 (range 1 to 4), which correlates with minimal to much improvement. Three patients were very much improved (1), two patients were much improved (2), two patients showed minimal improvement (3), and one showed no change (4) after clinical review by a board-certified psychiatrist. A similar pattern arose using the CGI-E. Mean CGI-E of the sample was 5.0 (range 1 to 13), which correlates with moderate therapeutic efficacy. One patient showed no efficacy of the drug (13), five patients showed moderate efficacy of the drug (5), and two patients showed marked efficacy (1).

The resulting scores based on the CGI metrics provide primitive evidence about the efficacy of Cariprazine on treating ASD and ID. Considering that the mean of the patients was ranked in the category of severe illness, we are given a good baseline to compare from. The CGI-I and CGI-E scales showed how most of the patients’ disease state did improve after treatment but at varying degrees. Although one patient did not improve after treatment, that patients’ symptoms did not worsen either and there were no adverse events reported. The various responses to the treatment hint at the possibility of some intrinsic factors that may be leading to different degrees of efficacy; a potential focal point for future studies. Additionally, the ages within the test group had a large range so treatment results on children and adults should be separated in future studies.
Conclusion

87.5% of patients treated with Cariprazine in this study demonstrated minimal to very much improvement as defined by a decrease in aggression, impulsivity, and/or self-injurious behavior using the CGI-I parameter. No patients being treated with Cariprazine exhibited worsening of clinical symptoms. There were no serious adverse drug reactions reported while patients were undergoing treatment with Cariprazine.

Cariprazine was combined with other atypical antipsychotics in six out of eight cases without evidence of cross-reactivity. Cariprazine was combined with anti-epileptic drugs in three patients without evidence of cross-reactivity. These findings suggest that Cariprazine, a second-generation atypical antipsychotic, may be effective in reducing symptoms of aggression, impulsivity, and self-injurious behavior in patients diagnosed with ASD and ID when other interventions have been tried unsuccessfully. Further investigations with Cariprazine in this patient population are warranted. Dr Cohen is a consultant to Allergan Pharmaceuticals, Sunovion Pharmaceuticals, Ironshore Pharmaceuticals, Neurocrine Pharmaceuticals and Neos Pharmaceuticals.

Acknowledgement

Dr Cohen is a consultant to Allergan Pharmaceuticals, Sunovion Pharmaceuticals, Ironshore Pharmaceuticals, Neurocrine Pharmaceuticals and Neos Pharmaceuticals.

References


